Alumis' Envudeucitinib Delivers Robust Skin Clearance and Symptom Relief in Plaque Psoriasis Trials

New Phase 3 data shows envudeucitinib's potential as a leading oral therapy for moderate-to-severe plaque psoriasis

Mar. 28, 2026 at 6:05pm

Got story updates? Submit your updates here. ›

Alumis Inc. announced positive results from two Phase 3 clinical trials evaluating envudeucitinib, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate-to-severe plaque psoriasis. The data, presented at the 2026 American Academy of Dermatology Annual Meeting, showed that envudeucitinib achieved high rates of skin clearance, quality-of-life improvements, and itch relief as early as Week 4, with continued deepening of responses through Week 24.

Why it matters

Plaque psoriasis is a chronic, immune-mediated disease that affects over 8 million adults in the U.S. and can significantly disrupt daily life, especially when high-impact areas like the scalp are involved. Many patients remain inadequately controlled on current oral and topical treatments, underscoring the need for more effective, safe, and durable oral options that address the full burden of the disease.

The details

In the two Phase 3 trials, envudeucitinib demonstrated robust skin clearance, with 68.0% and 62.1% of patients achieving a PASI 90 response by Week 24. PASI 100 responses, indicating complete skin clearance, were achieved by 41.0% and 39.5% of patients. Envudeucitinib also showed rapid improvements in scalp psoriasis, with around three out of four patients achieving clear or almost clear scalp by Week 24. Importantly, quality-of-life and itch improvements emerged before PASI 90 skin clearance and continued to deepen through Week 24.

  • The data were presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
  • Alumis plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026.

The players

Alumis Inc.

A late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases.

Dr. Andrew Blauvelt

A leading dermatologist and psoriasis expert.

Dr. Jörn Drappa

Chief Medical Officer of Alumis.

Envudeucitinib

A next-generation, highly selective, oral allosteric inhibitor of tyrosine kinase 2 (TYK2) being developed by Alumis for the treatment of moderate-to-severe plaque psoriasis.

ONWARD1 and ONWARD2

The Phase 3 clinical trials evaluating envudeucitinib in adults with moderate-to-severe plaque psoriasis.

Got photos? Submit your photos here. ›

What they’re saying

“What stands out with envudeucitinib in these trials is how quickly patients begin to feel relief from symptoms, and how deeply those improvements continue to build.”

— Dr. Andrew Blauvelt, Leading dermatologist and psoriasis expert

“Envudeucitinib delivered the level of skin clearance, symptom relief, and safety in Phase 3 that the TYK2 mechanism has long promised but that has not been fully realized—until now—with sustained, maximal 24-hour inhibition of the IL-23 / IL-17 pathways.”

— Dr. Jörn Drappa, Chief Medical Officer of Alumis

What’s next

Alumis is continuing to evaluate the long-term efficacy and safety of envudeucitinib in the ONWARD3 long-term extension trial and plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of this year.

The takeaway

The robust skin clearance, symptom relief, and favorable safety profile observed with envudeucitinib in these Phase 3 trials underscore its potential to be a leading oral therapy for patients with moderate-to-severe plaque psoriasis, addressing an important unmet need in this chronic, debilitating condition.